Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice.
Blagovic K, Smith CK, Ramakrishnan A, Moore L, Soto DR, Thompson Z, Stockmann AP, Kruszelnicki S, Thakkar A, Murray J, Torres S, Wondimagegnhu B, Yi R, Dadgar M, Paracha AM, Page C, Clear L, Chaudhry OA, Myint M, Bridgen DT, Gilbert JB, Seidl KJ, Sharei A, Loughhead S, Bernstein H, Yarar D.
Blagovic K, et al.
Front Immunol. 2022 Oct 3;13:1015585. doi: 10.3389/fimmu.2022.1015585. eCollection 2022.
Front Immunol. 2022.
PMID: 36263022
Free PMC article.